A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The 12 lead electrocardiogram (ECG) contains quantitative measures reflecting diverse aspects of electrophysiology that might provide insights into mechanisms underlying these associations.

A total of 911 study participants underwent ECGs at baseline and again at 2 years after the randomization.

Who Took Part

According to the abstract, 911 participants were involved.

The age groups tagged for this paper are middle-aged adults.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The 12 lead electrocardiogram (ECG) contains quantitative measures reflecting diverse aspects of electrophysiology that might provide insights into mechanisms underlying these associations.

The subject headings attached to it are Fatty Acids, Omega-3, Cholecalciferol, Vitamin D, Dietary Supplements and Electrocardiography.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 911 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2023 (Scientific reports), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.